JP2002154966A - Aluminum acetylsalicylate-containing composition - Google Patents
Aluminum acetylsalicylate-containing compositionInfo
- Publication number
- JP2002154966A JP2002154966A JP2000356123A JP2000356123A JP2002154966A JP 2002154966 A JP2002154966 A JP 2002154966A JP 2000356123 A JP2000356123 A JP 2000356123A JP 2000356123 A JP2000356123 A JP 2000356123A JP 2002154966 A JP2002154966 A JP 2002154966A
- Authority
- JP
- Japan
- Prior art keywords
- aluminum
- acetylsalicylate
- mixed
- aluminum acetylsalicylate
- magnesium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GKJRJGXKDYCFNF-UHFFFAOYSA-K aluminum;2-acetyloxybenzoate Chemical compound [Al+3].CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O.CC(=O)OC1=CC=CC=C1C([O-])=O GKJRJGXKDYCFNF-UHFFFAOYSA-K 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 title abstract description 8
- 239000003159 antacid agent Substances 0.000 claims abstract description 10
- 239000008247 solid mixture Substances 0.000 claims abstract description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical class [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 13
- 229940069428 antacid Drugs 0.000 claims description 9
- 230000001458 anti-acid effect Effects 0.000 claims description 9
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 108010011485 Aspartame Proteins 0.000 description 8
- 239000000605 aspartame Substances 0.000 description 8
- 235000010357 aspartame Nutrition 0.000 description 8
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 8
- 229960003438 aspartame Drugs 0.000 description 8
- 239000007910 chewable tablet Substances 0.000 description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 7
- 239000004386 Erythritol Substances 0.000 description 7
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 7
- 229930195725 Mannitol Natural products 0.000 description 7
- 235000019414 erythritol Nutrition 0.000 description 7
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 7
- 229940009714 erythritol Drugs 0.000 description 7
- 239000000594 mannitol Substances 0.000 description 7
- 235000010355 mannitol Nutrition 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229920001592 potato starch Polymers 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 235000013527 bean curd Nutrition 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 3
- 229960002449 glycine Drugs 0.000 description 3
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- 239000000395 magnesium oxide Substances 0.000 description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 229940008027 aluminum hydroxide / magnesium carbonate Drugs 0.000 description 2
- WMGSQTMJHBYJMQ-UHFFFAOYSA-N aluminum;magnesium;silicate Chemical compound [Mg+2].[Al+3].[O-][Si]([O-])([O-])[O-] WMGSQTMJHBYJMQ-UHFFFAOYSA-N 0.000 description 2
- 235000019658 bitter taste Nutrition 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 238000000975 co-precipitation Methods 0.000 description 2
- -1 magnesium silicate aluminate Chemical class 0.000 description 2
- 229940088417 precipitated calcium carbonate Drugs 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- BWZOPYPOZJBVLQ-UHFFFAOYSA-K aluminium glycinate Chemical compound O[Al+]O.NCC([O-])=O BWZOPYPOZJBVLQ-UHFFFAOYSA-K 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940024545 aluminum hydroxide Drugs 0.000 description 1
- 229940024546 aluminum hydroxide gel Drugs 0.000 description 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- GDVKFRBCXAPAQJ-UHFFFAOYSA-A dialuminum;hexamagnesium;carbonate;hexadecahydroxide Chemical compound [OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Al+3].[Al+3].[O-]C([O-])=O GDVKFRBCXAPAQJ-UHFFFAOYSA-A 0.000 description 1
- XLIDPNGFCHXNGX-UHFFFAOYSA-N dialuminum;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Al+3].[Si+4] XLIDPNGFCHXNGX-UHFFFAOYSA-N 0.000 description 1
- 229940015826 dihydroxyaluminum aminoacetate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000008123 high-intensity sweetener Substances 0.000 description 1
- 229960001545 hydrotalcite Drugs 0.000 description 1
- 229910001701 hydrotalcite Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229960000816 magnesium hydroxide Drugs 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052919 magnesium silicate Inorganic materials 0.000 description 1
- 235000019792 magnesium silicate Nutrition 0.000 description 1
- ZADYMNAVLSWLEQ-UHFFFAOYSA-N magnesium;oxygen(2-);silicon(4+) Chemical compound [O-2].[O-2].[O-2].[Mg+2].[Si+4] ZADYMNAVLSWLEQ-UHFFFAOYSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000013615 non-nutritive sweetener Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- GRLPQNLYRHEGIJ-UHFFFAOYSA-J potassium aluminium sulfate Chemical compound [Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GRLPQNLYRHEGIJ-UHFFFAOYSA-J 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明はアセチルサリチル酸
アルミニウム含有固形組成物に関する。The present invention relates to a solid composition containing aluminum acetylsalicylate.
【０００２】[0002]
【従来の技術】医薬品の固形製剤を服用するときには、
薬剤によっては風味が悪く、服用性が悪いことがある。
その風味に影響する因子として、活性成分の苦味や、い
わゆる粉っぽさなどがあげられる。苦味に関しては、糖
類やアスパルテーム、サッカリンなどの高甘味料の添加
や水難溶性高分子によるコーティング、ワックス類によ
るマイクロカプセル化などの方法で隠蔽する技術が広く
知られている。しかし、粉っぽさの改善に関してはほと
んど報告されていない。2. Description of the Related Art When taking solid pharmaceutical preparations,
Some drugs have an unpleasant taste and are inconvenient to take.
Factors affecting the flavor include the bitterness of the active ingredient and so-called powderyness. With respect to bitterness, techniques for concealing it by adding sugars, aspartame, saccharin, or other high-intensity sweeteners, coating with a poorly water-soluble polymer, or microencapsulating with waxes are widely known. However, little has been reported about improving the powderiness.
【０００３】アセチルサリチル酸アルミニウムも固形製
剤として服用した場合、粉っぽさを感じるという問題が
あった。[0003] There has been a problem that aluminum acetylsalicylate also feels powdery when taken as a solid preparation.
【０００４】[0004]
【発明が解決しようとする課題】本発明は、アセチルサ
リチル酸アルミニウムの服用性を向上することを目的と
する。SUMMARY OF THE INVENTION An object of the present invention is to improve the ingestibility of aluminum acetylsalicylate.
【０００５】[0005]
【課題を解決するための手段】本発明者らは、アセチル
サリチル酸アルミニウムの服用性を向上するべく鋭意検
討を行った結果、アセチルサリチル酸アルミニウムがア
ルカリ性水溶液中で溶解性が向上することに着目し、ア
セチルサリチル酸アルミニウム含有組成物に制酸剤を配
合することで口中における溶解性が向上し、粉っぽさが
低減されることを見出し本発明を完成した。Means for Solving the Problems The present inventors have made intensive studies to improve the ingestibility of aluminum acetylsalicylate, and as a result, have noticed that aluminum acetylsalicylate has improved solubility in an alkaline aqueous solution. The inventor has found that by adding an antacid to the aluminum acetylsalicylate-containing composition, the solubility in the mouth is improved and the powderiness is reduced, thus completing the present invention.
【０００６】すなわち本発明はアセチルサリチル酸アル
ミニウムおよび制酸剤を含有することを特徴とする固形
組成物である。That is, the present invention is a solid composition comprising aluminum acetylsalicylate and an antacid.
【０００７】[0007]
【発明の実施の形態】本発明の組成物は、顆粒剤、散
剤、錠剤（特にチュアブル錠）などの通常の医薬品の形
態を使用することができる。BEST MODE FOR CARRYING OUT THE INVENTION The composition of the present invention can be used in the form of usual pharmaceuticals such as granules, powders and tablets (particularly chewable tablets).
【０００８】本発明のアセチルサリチル酸アルミニウム
の配合量は、医薬品としての薬効を発現する程度に配合
することができる。[0008] The aluminum acetylsalicylate of the present invention can be blended in such an amount as to exhibit its medicinal properties.
【０００９】具体的には１日量で４００mg〜２０００mg
程度の量を配合することができ、１日１回〜数回に分け
て投与できる量を配合し製剤とすることができる。Specifically, a daily dose of 400 mg to 2000 mg
A small amount can be added, and an amount that can be administered once or several times a day can be added to form a preparation.
【００１０】本発明において、制酸剤は通常医薬品に使
用する制酸剤であれば特に限定はなく使用でき、具体的
には乾燥水酸化アルミニウムゲル、ケイ酸アルミン酸マ
グネシウム、ケイ酸マグネシウム、合成ケイ酸アルミニ
ウム、合成ヒドロタルサイト、酸化マグネシウム、水酸
化アルミナマグネシウム、水酸化アルミニウムゲル、水
酸化アルミニウム・炭酸水素ナトリウム共沈生成物、水
酸化アルミニウム・炭酸マグネシウム混合乾燥ゲル、水
酸化アルミニウム・炭酸マグネシウム・炭酸カルシウム
共沈生成物、水酸化マグネシウム、炭酸水素ナトリウ
ム、炭酸マグネシウム、沈降炭酸カルシウム、メタケイ
酸アルミン酸マグネシウム、無水リン酸水素カルシウ
ム、リン酸水素カルシウム、烏賊骨、石決明、ボレイ、
アミノ酢酸、ジヒドロキシアルミニウムアミノアセテー
ト、ロートエキス及び水酸化マグネシウム・硫酸アルミ
ニウムカリウムの共沈生成物が好ましく、酸化マグネシ
ウム、アミノ酢酸およびメタケイ酸アルミン酸マグネシ
ウムがさらに好ましい。ここで、制酸剤は単品、または
数種類を混合して用いることもできる。In the present invention, the antacid can be used without any particular limitation as long as it is an antacid normally used for pharmaceuticals. Specifically, dried aluminum hydroxide gel, magnesium silicate aluminate, magnesium silicate, synthetic antacid Aluminum silicate, Synthetic hydrotalcite, Magnesium oxide, Alumina magnesium hydroxide, Aluminum hydroxide gel, Aluminum hydroxide / sodium hydrogen carbonate coprecipitation product, Aluminum hydroxide / magnesium carbonate mixed dry gel, Aluminum hydroxide / magnesium carbonate・ Calcium carbonate coprecipitation product, magnesium hydroxide, sodium hydrogen carbonate, magnesium carbonate, precipitated calcium carbonate, magnesium metasilicate aluminate, anhydrous calcium hydrogen phosphate, calcium hydrogen phosphate, squid bone, stone decision, volley,
A co-precipitated product of aminoacetic acid, dihydroxyaluminum aminoacetate, funnel extract and magnesium hydroxide / potassium aluminum sulfate is preferred, and magnesium oxide, aminoacetic acid and magnesium aluminate metasilicate are more preferred. Here, the antacid can be used alone or as a mixture of several types.
【００１１】また、アセチルサリチル酸アルミニウムに
対する制酸剤の配合比率は１〜２００質量％であるが、
好ましくは５〜１００質量％、更に好ましくは５〜８０
質量％である。The compounding ratio of the antacid to aluminum acetylsalicylate is 1 to 200% by mass.
Preferably 5 to 100% by mass, more preferably 5 to 80% by mass.
% By mass.
【００１２】本発明の組成物は、本発明の効果を損なわ
ない内服可能な成分を適宜配合することができ、通常の
医薬品製造方法により製造することができる。[0012] The composition of the present invention can be appropriately mixed with an orally administrable component which does not impair the effects of the present invention, and can be produced by a usual pharmaceutical production method.
【００１３】[0013]
【発明の効果】本発明により、アセチルサリチル酸アル
ミニウムを配合した服用性の良好な固形組成物の提供が
可能になった。According to the present invention, it has become possible to provide a solid composition having good ingestibility, which contains aluminum acetylsalicylate.
【００１４】[0014]
【実施例】以下、実施例をあげて本発明の組成物を具体
的に説明する。 実施例１ アセチルサリチル酸アルミニウム２０００ｇ、酸化マグ
ネシウム５００ｇ、バレイショデンプン９０ｇ、フント
ウ１００ｇ、マンニトール５０ｇ、エリスリトール５０
ｇ、アスパルテーム３０ｇ、ポリビニルピロリドン１５
０ｇを混合し、バーチカルグラニュレーター２５Ｌ（パ
ウレック社製）にて精製水で造粒し、流動層乾燥機にて
乾燥し、ステアリン酸マグネシウム３０ｇを加えて混合
し、ロータリー打錠機（菊水製作所社製）により１錠５
００ｍｇのチュアブル錠を得た。The composition of the present invention will be described below in detail with reference to examples. Example 1 2000 g of aluminum acetylsalicylate, 500 g of magnesium oxide, 90 g of potato starch, 100 g of tofu, 50 g of mannitol, 50 erythritol
g, aspartame 30 g, polyvinylpyrrolidone 15
0 g, mixed with purified water using Vertical Granulator 25L (manufactured by Powrex), dried with a fluidized bed drier, mixed with 30 g of magnesium stearate, and mixed with a rotary tableting machine (Kikusui Seisakusho Co., Ltd.). 5 tablets per product
00 mg of chewable tablets were obtained.
【００１５】実施例２ アセチルサリチル酸アルミニウム２０００ｇ、メタケイ
酸アルミン酸マグネシウム５００ｇ、バレイショデンプ
ン９０ｇ、フントウ１００ｇ、マンニトール５０ｇ、エ
リスリトール５０ｇ、アスパルテーム３０ｇ、ポリビニ
ルピロリドン１５０ｇを混合し、バーチカルグラニュレ
ーター２５Ｌ（パウレック社製）にて精製水で造粒し、
流動層乾燥機にて乾燥し、ステアリン酸マグネシウム３
０ｇを加えて混合し、ロータリー打錠機（菊水製作所社
製）により１錠５００ｍｇのチュアブル錠を得た。Example 2 2000 g of aluminum acetylsalicylate, 500 g of magnesium aluminate metasilicate, 90 g of potato starch, 100 g of tofu, 50 g of mannitol, 50 g of erythritol, 30 g of aspartame, and 150 g of polyvinylpyrrolidone were mixed, and a vertical granulator 25L (manufactured by Powrex) Granulated with purified water at
Dry with a fluid bed dryer and add magnesium stearate 3
0 g was added and mixed, and 500 mg of a chewable tablet was obtained using a rotary tableting machine (manufactured by Kikusui Seisakusho).
【００１６】実施例３ アセチルサリチル酸アルミニウム２０００ｇ、炭酸水素
ナトリウム５００ｇ、バレイショデンプン９０ｇ、フン
トウ１００ｇ、マンニトール５０ｇ、エリスリトール５
０ｇ、アスパルテーム３０ｇ、ポリビニルピロリドン１
５０ｇを混合し、バーチカルグラニュレーター２５Ｌ
（パウレック社製）にて精製水で造粒し、流動層乾燥機
にて乾燥し、ステアリン酸マグネシウム３０ｇを加えて
混合し、ロータリー打錠機（菊水製作所社製）により１
錠５００ｍｇのチュアブル錠を得た。Example 3 2000 g of aluminum acetylsalicylate, 500 g of sodium bicarbonate, 90 g of potato starch, 100 g of tofu, 50 g of mannitol, 5 erythritol
0 g, aspartame 30 g, polyvinylpyrrolidone 1
50 g were mixed, and the vertical granulator was 25 L.
Granulated with purified water (made by Powrex), dried with a fluid bed dryer, mixed with 30 g of magnesium stearate, and mixed with a rotary tableting machine (manufactured by Kikusui Seisakusho).
500 mg of chewable tablets were obtained.
【００１７】実施例４ アセチルサリチル酸アルミニウム２０００ｇ、沈降炭酸
カルシウム５００ｇ、バレイショデンプン９０ｇ、フン
トウ１００ｇ、マンニトール５０ｇ、エリスリトール５
０ｇ、アスパルテーム３０ｇ、ポリビニルピロリドン１
５０ｇを混合し、バーチカルグラニュレーター２５Ｌ
（パウレック社製）にて精製水で造粒し、流動層乾燥機
にて乾燥し、ステアリン酸マグネシウム３０ｇを加えて
混合し、ロータリー打錠機（菊水製作所社製）により１
錠５００ｍｇのチュアブル錠を得た。Example 4 2000 g of aluminum acetylsalicylate, 500 g of precipitated calcium carbonate, 90 g of potato starch, 100 g of tofu, 50 g of mannitol, 5 erythritol
0 g, aspartame 30 g, polyvinylpyrrolidone 1
50 g were mixed, and the vertical granulator was 25 L.
Granulated with purified water (made by Powrex), dried with a fluid bed dryer, mixed with 30 g of magnesium stearate, and mixed with a rotary tableting machine (manufactured by Kikusui Seisakusho).
500 mg of chewable tablets were obtained.
【００１８】実施例５ アセチルサリチル酸アルミニウム２０００ｇ、無水リン
酸水素カルシウム５００ｇ、バレイショデンプン９０
ｇ、フントウ１００ｇ、マンニトール５０ｇ、エリスリ
トール５０ｇ、アスパルテーム３０ｇ、ポリビニルピロ
リドン１５０ｇを混合し、バーチカルグラニュレーター
２５Ｌ（パウレック社製）にて精製水で造粒し、流動層
乾燥機にて乾燥し、ステアリン酸マグネシウム３０ｇを
加えて混合し、ロータリー打錠機（菊水製作所社製）に
より１錠５００ｍｇのチュアブル錠を得た。Example 5 2000 g of aluminum acetylsalicylate, 500 g of anhydrous calcium hydrogen phosphate, potato starch 90
g, funto 100 g, mannitol 50 g, erythritol 50 g, aspartame 30 g, polyvinylpyrrolidone 150 g were mixed, granulated with purified water using a vertical granulator 25 L (manufactured by Powrex), dried with a fluidized bed drier, and stearic acid was dried. 30 g of magnesium was added and mixed, and 500 mg of a chewable tablet was obtained using a rotary tableting machine (manufactured by Kikusui Seisakusho).
【００１９】実施例６ アセチルサリチル酸アルミニウム２０００ｇ、リン酸水
素カルシウム５００ｇ、バレイショデンプン９０ｇ、フ
ントウ１００ｇ、マンニトール５０ｇ、エリスリトール
５０ｇ、アスパルテーム３０ｇ、ポリビニルピロリドン
１５０ｇを混合し、バーチカルグラニュレーター２５Ｌ
（パウレック社製）にて精製水で造粒し、流動層乾燥機
にて乾燥し、ステアリン酸マグネシウム３０ｇを加えて
混合し、ロータリー打錠機（菊水製作所社製）により１
錠５００ｍｇのチュアブル錠を得た。Example 6 2000 g of aluminum acetylsalicylate, 500 g of calcium hydrogen phosphate, 90 g of potato starch, 100 g of tofu, 50 g of mannitol, 50 g of erythritol, 30 g of aspartame, and 150 g of polyvinylpyrrolidone were mixed together.
Granulated with purified water (made by Powrex), dried with a fluid bed dryer, mixed with 30 g of magnesium stearate, and mixed with a rotary tableting machine (manufactured by Kikusui Seisakusho).
500 mg of chewable tablets were obtained.
【００２０】実施例７ アセチルサリチル酸アルミニウム２０００ｇ、アミノ酢
酸５００ｇ、バレイショデンプン９０ｇ、フントウ１０
０ｇ、マンニトール５０ｇ、エリスリトール５０ｇ、ア
スパルテーム３０ｇ、ポリビニルピロリドン１５０ｇを
混合し、バーチカルグラニュレーター２５Ｌ（パウレッ
ク社製）にて精製水で造粒し、流動層乾燥機にて乾燥
し、ステアリン酸マグネシウム３０ｇを加えて混合し、
ロータリー打錠機（菊水製作所社製）により１錠５００
ｍｇのチュアブル錠を得た。Example 7 2000 g of aluminum acetylsalicylate, 500 g of aminoacetic acid, 90 g of potato starch, 10
0 g, mannitol 50 g, erythritol 50 g, aspartame 30 g, and polyvinylpyrrolidone 150 g were mixed, granulated with purified water using a vertical granulator 25 L (manufactured by Powrex), dried with a fluidized bed drier, and dried with a fluidized bed drier to obtain 30 g of magnesium stearate. Add and mix,
500 tablets per rotary tableting machine (Kikusui Seisakusho)
mg of chewable tablets were obtained.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 沼尾 正晴 東京都豊島区高田３丁目24番１号 大正製 薬株式会社内 Ｆターム(参考） 4C076 AA29 AA37 BB01 CC01 DD25T DD26T DD27T DD29T FF52 4C086 AA01 DA17 MA05 MA52 NA09 ZA07 ZA08 ────────────────────────────────────────────────── ─── Continuing from the front page (72) Inventor Masaharu Numao 3-24-1, Takada, Toshima-ku, Tokyo Taisho Seiyaku Co., Ltd. F-term (reference) 4C076 AA29 AA37 BB01 CC01 DD25T DD26T DD27T DD29T FF52 4C086 AA01 DA17 MA05 MA52 NA09 ZA07 ZA08
Claims (2)
酸剤を含有することを特徴とする固形組成物。1. A solid composition containing aluminum acetylsalicylate and an antacid.
酸剤を１〜２００質量％配合することを特徴とする請求
項１に記載する固形組成物2. The solid composition according to claim 1, wherein an antacid is blended in an amount of 1 to 200% by mass based on aluminum acetylsalicylate.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000356123A JP2002154966A (en) | 2000-11-22 | 2000-11-22 | Aluminum acetylsalicylate-containing composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000356123A JP2002154966A (en) | 2000-11-22 | 2000-11-22 | Aluminum acetylsalicylate-containing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002154966A true JP2002154966A (en) | 2002-05-28 |
Family
ID=18828427
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000356123A Pending JP2002154966A (en) | 2000-11-22 | 2000-11-22 | Aluminum acetylsalicylate-containing composition |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2002154966A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094812A1 (en) * | 2004-04-01 | 2005-10-13 | Ajinomoto Co., Inc. | Nateglinide-containing preparation |
| JPWO2012074110A1 (en) * | 2010-12-03 | 2014-05-19 | 武田薬品工業株式会社 | Orally disintegrating tablets |
| JP2015168681A (en) * | 2014-03-11 | 2015-09-28 | ライオン株式会社 | tablet |
-
2000
- 2000-11-22 JP JP2000356123A patent/JP2002154966A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005094812A1 (en) * | 2004-04-01 | 2005-10-13 | Ajinomoto Co., Inc. | Nateglinide-containing preparation |
| JPWO2012074110A1 (en) * | 2010-12-03 | 2014-05-19 | 武田薬品工業株式会社 | Orally disintegrating tablets |
| JP6037840B2 (en) * | 2010-12-03 | 2016-12-07 | 武田薬品工業株式会社 | Orally disintegrating tablets |
| JP2015168681A (en) * | 2014-03-11 | 2015-09-28 | ライオン株式会社 | tablet |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7216055B2 (en) | Pharmaceutical composition | |
| CA2311734C (en) | Flash-melt oral dosage formulation | |
| JP2009185082A (en) | Preparation for oral administration | |
| US8974824B2 (en) | Lanthanum composition | |
| JP5490347B2 (en) | Formulation for oral administration | |
| US6589507B1 (en) | Foaming antacid suspension tablets | |
| WO2004078171A1 (en) | Tablet containing water-absorbing amino acid | |
| EP2389070B1 (en) | Disintegrable formulations of lanthanum carbonate | |
| JP6803250B2 (en) | Orally disintegrating tablets containing eletriptan hydrobromic acid | |
| JP2002154966A (en) | Aluminum acetylsalicylate-containing composition | |
| JP2010241760A (en) | Tablet quickly disintegrable in oral cavity that has unpleasant taste reduced, and method for preparing the same | |
| JP2726498B2 (en) | Oral solid preparation | |
| JP5062872B2 (en) | Orally disintegrating tablets with reduced unpleasant taste | |
| JP4519444B2 (en) | Orally disintegrating tablets | |
| WO2022102457A1 (en) | Linagliptin-containing orally disintegrating tablet | |
| JP2000229855A (en) | Pravastatin sodium tablet | |
| CN100998594B (en) | Solid oral medicine composition containing amodiaquine | |
| JP2002154965A (en) | Aluminum acetylsalicylate-containing composition | |
| JP2616822B2 (en) | Calcium preparation | |
| JP2010053048A (en) | Irbesartan-containing pharmaceutical composition having mitigated bitter taste | |
| JPH11335280A (en) | Oral solid preparation | |
| JP2003002829A (en) | Pharmaceutical composition | |
| CN116635013A (en) | Orally dispersible powder composition | |
| JP2000273038A (en) | Tablet soluble in oral cavity | |
| JP2545479B2 (en) | Pharmaceutical composition |